Study comparing firsekibart to anakinra for adult-onset Still's disease
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests a new drug called firsekibart against an existing drug, anakinra, for people with active adult-onset Still's disease. It aims to see if firsekibart is more effective in controlling symptoms like fever, joint pain, and rash.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with adult-onset Still's disease based on specific criteria, including high fever, joint pain, and typical rash.
- Your disease is active, meaning you have fever or a high C-reactive protein level (CRP >10 mg/L).
- If you take steroids (like prednisone), your dose has been stable for at least 1 week and does not exceed 1 mg per kg of body weight per day.
- You have not used certain medications (like JAK inhibitors, anakinra, or some immunosuppressants) within a specific time before the trial starts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called picankibart to see if it helps people with active psoriatic arthritis who haven't gotten enough relief from standard treatments like NSAIDs or non-biologic DMARDs. It may be an option if you have at least 3 tender and 3 swollen joints and active or past plaque psoriasis.
This trial tests whether taking firsekibart (a gout prevention injection) on a regular schedule works better than taking it only when needed. You would be eligible if you've already completed 24 weeks of firsekibart without gout flares and are willing to continue gout-lowering medications.
This trial tests a new drug called Firsekibart for people with a specific type of systemic sclerosis (SSc) called diffuse cutaneous SSc. The goal is to see if it can safely improve skin tightness and other symptoms.
This study tests whether two injectable medicines (goflikicept and olokizumab) work safely as a second treatment for adults with Still's disease, a rare inflammatory condition. If you've already tried one treatment without enough improvement, this trial may help.
This trial tests adding a new drug, firsekibart, to standard immunoglobulin treatment for children with Kawasaki disease. The goal is to see if the combination is safe and works better than immunoglobulin alone.
This study tests whether a new drug called firsekibart can help prevent gout from coming back. If you've had multiple gout attacks in the past year and are currently having one, this trial may help you and advance gout treatment.
Hear when a new Still's Disease, Adult-Onset trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.